Researchers from New York City-based Icahn School of Medicine at Mount Sinai and Chapel Hill-based University of North Carolina School of Medicine established a joint IBD and COVID-19 registry to track how COVID-19 is affecting IBD patients. The registry currently has 528 patients from 33 countries.
Increased age, comorbidities and corticosteroids are all associated with IBD patients with severe cases of COVID-19. However, TNF antagonist therapies did not appear to be connected with severe COVID-19.
Erica Brenna, MD, a pediatric gastroenterology fellow at Chapel Hill-based UNC Children’s Hospital, commented on the registry, saying: “We established the registry to better characterize the clinical course of COVID-19 within the IBD patient population and evaluate the association between demographics, clinical characteristics, and IBD treatments on COVID-19 outcomes.”
More articles on surgery centers:
4 COVID-19 supply considerations for ASCs
5 hospitals, health systems opening or planning ASCs
ASCs reopening to patients: Check these 7 boxes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.